VOLUNTARY ANNOUNCEMENT - IVONESCIMAB MEETS OS KEY SECONDARY ENDPOINT IN INTERIM ANALYSIS OF HARMONI-2 STUDY, DEMONSTRATING STATISTICALLY SIGNIFICANT AND CLINICALLY MEANINGFUL BENEFIT VERSUS PEMBROLIZUMAB IN 1L PD-L1-POSITIVE NSCLC
Attachments
HKEX-EPS_20260903_12317216_0.PDF